Status:

COMPLETED

Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.

Lead Sponsor:

Amgen

Conditions:

Chemotherapy-induced Febrile Neutropenia

Eligibility:

All Genders

18+ years

Brief Summary

This is a prospective observational study investigating how physicians assess the risk of febrile neutropenia (FN) developing in patients who will receive chemotherapy. Approximately 150-200 investig...

Detailed Description

Although a formal hypothesis will not be tested in this observational study, it is hypothesized that the clinical risk factors ranked as the most important when conducting FN risk assessments by inves...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years old
  • Any stage NHL, small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), or breast cancer initiating a new chemotherapy course
  • Scheduled to receive one of the permitted standard dose chemotherapy regimens with an estimated intermediate (10%-20%) FN risk according to published data or guidelines (planned dose modifications +/-10% are allowable).
  • Before any study-specific procedure, the appropriate written informed consent must be obtained where this is required by local regulations

Exclusion

  • Ongoing or planned concurrent participation in any clinical study involving Investigational Product that has not been approved by the European Medicines Agency (EMA) or competent authority for any indication,
  • Ongoing or planned concurrent participation in any clinical study where the administration of Colony Stimulating Factor (CSF) is determined by the protocol (clinical trials on an approved drug and observational trials are permitted as long as these do not mandate how neutropenia should be treated)
  • Prior stem-cell transplantation (includes bone marrow transplantation)

Key Trial Info

Start Date :

December 1 2012

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2013

Estimated Enrollment :

1007 Patients enrolled

Trial Details

Trial ID

NCT01813721

Start Date

December 1 2012

End Date

December 1 2013

Last Update

March 15 2017

Active Locations (90)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 23 (90 locations)

1

Research Site

Tweed Heads, New South Wales, Australia, 2485

2

Research Site

Bendigo, Victoria, Australia, 3550

3

Research Site

Shepparton, Victoria, Australia, 3630

4

Research Site

Wodonga, Victoria, Australia, 3690

Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy. | DecenTrialz